Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Janeiro 2024 - 10:00AM
Business Wire
Immunome, Inc. (Nasdaq: IMNM), a biotechnology
company focused on developing first-in-class and best-in-class
targeted cancer therapies, today announced that Clay Siegall, PhD,
President and CEO of Immunome, will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Thursday, January 8 at 7:30 a.m.
PT.
Interested parties can access the live audio webcast for this
conference from the Investor Relations section of the company’s
website at www.immunome.com. The webcast replay will be available
after the conclusion of the live presentation for approximately 90
days.
About Immunome, Inc.
Immunome is a biotechnology company dedicated to developing
first-in-class and best-in-class targeted cancer therapies. Our
portfolio pursues each target with a modality appropriate to its
biology, including radioligand therapies, ADCs, and
immunotherapies. We believe that pursuing underexplored targets
with appropriate drug modalities leads to transformative therapies.
Our proprietary memory B cell hybridoma technology allows for the
rapid screening and functional characterization of novel antibodies
and targets.
For more information, visit www.immunome.com or follow us on
Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240103115774/en/
Investor Contact
Max Rosett Interim Chief Financial Officer
investors@immunome.com
Immunome (NASDAQ:IMNM)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Immunome (NASDAQ:IMNM)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024